

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**RainMed**

**Rainmed Medical Limited**

**潤邁德醫療有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2297)**

## **VOLUNTARY ANNOUNCEMENT**

### **REGISTRATION IN AUSTRALIA FOR CAFFR SYSTEM**

This announcement is made by Rainmed Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement and product registration progress of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that coronary angiography-derived fractional flow reserve system (“**caFFR System**”) self-developed by the Company was successfully registered in the Commonwealth of Australia (“**Australia**”) and was approved by Therapeutic Goods Administration (“**TGA**”).

Our caFFR System can be utilized for precision diagnosis of coronary artery diseases (“**CAD**”), which evaluate the severity of myocardial ischemia arising from coronary artery stenosis (the underlying causes of CAD). It is designed to eliminate the usage of pressure wires, significantly reduce the risk of technical errors and operation time, and improve physiological assessment. Prior to obtaining the approval from TGA, our caFFR System has obtained the CE Mark in Europe and the National Medical Products Administration’s approval in China, and was successfully registered in the Republic of Serbia and the Republic of South Africa. As part of our international strategy, in addition to our continuous expansion in the China market, we also endeavor to gain international recognition for our business. The successful registration in Australia marks another solid step forward on the Group’s international roadmap, and will facilitate the promotion and application of our caFFR System in Australia and related regions.

**Cautionary Statement:** The Company cannot guarantee the future prospects of our caFFR System. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board  
**Rainmed Medical Limited**  
**Huo Yunfei**

*Chairman of the Board and Executive Director*

Hong Kong, September 29, 2022

*As at the date of this announcement, the Board comprises Mr. Huo Yunfei, Mr. Lyu Yonghui, Mr. Zhang Liang and Ms. Gu Yang as executive directors, Mr. Wang Lin and Mr. Heng Lei as non-executive directors, and Mr. Liu Shuen Kong, Mr. Li Ho Man and Mr. Lau Tsz Ho Tony as independent non-executive directors.*